EUVIMEDEUVIMED entdecken
Open Access

High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers

Elsie Ennin iD, Niharika Mallepally, Myra Ali, Layla Shojaie, Sean Dewberry, Melissa Trieu, Evanthia T Roussos Torres, Kali Zhou iD, Jeffrey Kahn iD, Jennifer L Dodge, Lily Dara

Liver International · 2025

DOI: 10.1111/liv.70255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Elsie Ennin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Immune Checkpoint Inhibitors, Liver Neoplasms, Sorafenib. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Immune checkpoint inhibitors (ICIs) are therapy for many malignancies including hepatocellular carcinoma (HCC), yet the impact of HCC on immune‐mediated liver injury from checkpoint inhibitors (ILICI) remains poorly understood and no direct comparison exists for hepatotoxicity rates between ICI and sorafenib in HCC.

Methods

In this retrospective cohort study, we extracted data on adult patients treated with five ICI regimens for HCC or non‐HCC cancers, and HCC patients who received sorafenib between 2010 and 2020. The primary outcome was grade ≥ 3 ILICI or sorafenib (DILI). Logistic regression estimated adjusted odds ratios (OR) for liver injury.

Results

We identified 530 patients, 129 (24%) HCC‐ICI, 256 (48%) non‐HCC ICI, and 145 (27%) HCC‐sorafenib. Compared to non‐HCC ICI, HCC‐ICI and HCC‐sorafenib were more often male (57%, 82%, 77%), Hispanic (14%, 35%, 34%), and cirrhotic (1%, 85%, 88%). Twenty‐three patients developed grade ≥ 3 ILICI. ILICI incidence was higher for HCC‐ICI (11%, CI 6–18) versus non‐HCC ICI (4%, CI 2–6, p = 0.006) and DILI in HCC‐sorafenib (3%, CI 1–8, p = 0.02) with incidence highest for ipilimumab‐nivolumab (HCC‐ICI 42%, CI 15–72 versus non‐HCC 10%, CI 3–24; p = 0.02). On multivariable regression, ILICI was associated with HCC (OR 4.5, CI 1.8–11.4, p = 0.002) and treatment with ipilimumab‐nivolumab (OR 6.9, CI 2.6–18.3, p < 0.001). Incidence of liver injury in HCC remained elevated for ICI versus sorafenib (OR 3.5, CI 1.2–10.4, p = 0.02).

Conclusions

We identified an elevated risk of liver injury in HCC patients receiving ICIs compared to ICI‐treated non‐HCC cancers and sorafenib‐treated HCC, with dual ipilimumab‐nivolumab therapy carrying the highest risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularImmune Checkpoint InhibitorsLiver NeoplasmsSorafenibChemical and Drug Induced Liver InjuryHumansMaleFemaleRetrospective StudiesMiddle AgedAgedIncidenceLogistic ModelsAdult

Stichwörter der Autor:innen

CTLA‐4ILICIPD‐1immune‐related adverse eventsimmunotherapyliver injury

Substanzen

Immune Checkpoint InhibitorsSorafenib

Autor:innen und Institutionen

  • Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
  • Department of Medicine, Huntington Health, Pasadena, California, USA.
  • Division of Gastrointestinal and Liver Diseases, Research Center for Liver Disease, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Division of Hematology and Oncology, Norris Comprehensive Cancer Center, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

ORCID-Profile: Elsie Ennin, Kali Zhou, Jeffrey Kahn

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Ennin, E., Mallepally, N., Ali, M., Shojaie, L., Dewberry, S., Trieu, M., Torres, E. T. R., Zhou, K., Kahn, J., Dodge, J. L., & Dara, L. (2025). High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers. Liver International. https://doi.org/10.1111/liv.70255

Vancouver

Ennin E, Mallepally N, Ali M, Shojaie L, Dewberry S, Trieu M, et al. High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers. Liver International. 2025. doi:10.1111/liv.70255

BibTeX
@article{Ennin2025,
  author = {Ennin, Elsie and Mallepally, Niharika and Ali, Myra and Shojaie, Layla and Dewberry, Sean and Trieu, Melissa and Torres, Evanthia T Roussos and Zhou, Kali and Kahn, Jeffrey and Dodge, Jennifer L and Dara, Lily},
  title = {High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70255}
}
Kostenlos starten →